

September 26, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Update on acquisition of stake in Sunshine Healthcare Limited, Ghana

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

With reference to the captioned subject and in continuation of our earlier intimation dated July 24, 2026, regarding the approval accorded by the Board of Dr Lal PathLabs FZCO, Dubai (DLPL Dubai), Wholly Owned Subsidiary of the Company, for the acquisition of stake in Sunshine Healthcare Limited (“SHL”), Ghana.

We wish to inform you that DLPL Dubai, has completed the acquisition of 80% stake in SHL, in accordance with the agreement and prevailing provisions applicable in Ghana. Accordingly, SHL is a step-down subsidiary of the Company.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, have already been duly intimated in the earlier intimation dated July 24, 2026.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer